Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT

Inclusion Criteria: 1\. Acute myeloid leukemia was diagnosed according to the 2016ELN criteria with any of the following: 1. ELN prognostic stratification high-risk group (see Appendix for criteria) 2. Non-remission (NR) AML: including primary refractory AML and NR patients after relapse. 2\. Patients must have a suitable hematopoietic stem-cell donor. 1. Patients had to have a qualified haploidentical young male (≤30 years old) or female with a history of pregnancy; 2. Related donors had to be related donors matched 5/10-7/10 for HLA-A, -B, -C, -DQB1 and -DRB1 3. All the enrolled patients received a unified GVHD prevention regimen based on ATG and PTCy Exclusion Criteria: 1. Intermediate-low risk AML patients (ELN criteria); 2. Patients with extramedullary active lesions at the time of transplantation; 3. Haploidentical collateral donors; 4. Patients who refused allogeneic hematopoietic stem cell transplantation;